Oncology, Biosimilars & Specialty Pharmaceuticals
Three connected areas where strong scientific, regulatory and commercial capabilities can create sustainable access to high-quality medicines.
Oncology
Oncology is the principal therapeutic focus of Uniphar Pakistan.
We aim to build a comprehensive and commercially sustainable portfolio covering established chemotherapy products, targeted therapies, supportive care and selected innovative or specialty treatments.
- Oncology injectables
- Oral oncology medicines
- Targeted and specialty therapies
- Onco-hematology
- Supportive-care products
- Hospital and institutional oncology products
Biosimilars & Complex Biologics
Uniphar is developing opportunities in biosimilars and complex biologic therapies through international partnerships and portfolio development.
The focus is on products where strong scientific, regulatory and commercial capabilities can create sustainable access.
- Oncology biosimilars
- Monoclonal antibodies and complex biologics
- Selected specialty biologic therapies
- Future opportunities in high-value complex molecules
Specialty Pharmaceuticals
Alongside oncology and biosimilars, Uniphar evaluates selected specialty medicines where differentiated products, reliable manufacturing and disciplined market access can create meaningful healthcare impact.
- Differentiated products
- Reliable manufacturing
- Disciplined market access
- Meaningful healthcare impact
Explore a Partnership
Let’s build the next generation of specialty pharmaceutical opportunities together.